Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

A non-linear association between blood tumor mutation burden and prognosis in NSCLC patients receiving atezolizumab.

Oncoimmunology - 1 Jan 2020

Nie Wei, Qian Jie, Xu Mi-Die, Gu Kai, Qian Fang-Fei, Hu Min-Juan, Lu Jun, Gan Lu, Zhang Xue-Yan, Cao Shu-Hui, Li Jing-Wen, Wang Yue, Zhang Bo, Wang Shu-Yuan, Hu Fang, Li Chang-Hui, Zhong Hua, Han Bao-Hui

Abstract excerpt

A significant association between high blood-based tumor mutational burden (bTMB) and improved progression-free survival (PFS) was observed in advanced non-small cell lung cancer (NSCLC) receiving atezolizumab. However, this result was unrepeatable in a recent prospective study. We hypothesized that there might be a non-linear association between bTMB and survival. This study used the clinical and genetic data...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Prognosis
Share to Antibodies, Monoclonal, Humanized

Methodology Data sources Editorial policy Privacy Delete account & data About Contact Helena Bioinformatics

Share to Cancer Genomics and Diagnostics

Share to Cancer Immunotherapy and Biomarkers

Share to Carcinoma, Non-Small-Cell Lung

Share to Lung Cancer Treatments and Mutations

Share to Lung Neoplasms

Share to Mutation

Source

Open in PubMed Open full text

Identifiers

PMID: 32158623
DOI: 10.1080/2162402X.2020.1731072
PMCID: PMC7051187

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-08.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence. Graph snapshot: 2026-09-29.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

A non-linear association between blood tumor mutation burden and prognosis in NSCLC patients receiving atezolizumab.PMID 32158623Read ↗

Development and validation of a blood-based genomic mutation signature to predict the clinical outcomes of atezolizumab therapy in NSCLC.Semantic proximity Read ↗

A 5-Genomic Mutation Signature Can Predict the Survival for Patients With NSCLC Receiving Atezolizumab.Semantic proximity Read ↗

Advanced Non-Small Cell Lung Cancer Patients With Low Tumor Mutation Burden Might Derive Benefit From Immunotherapy.Semantic proximity Read ↗

Prognostic and Predictive Value of Blood Tumor Mutational Burden in Patients With Lung Cancer Treated With Docetaxel.Semantic proximity Read ↗

Tumor mutational burden adjusted by neutrophil-to-lymphocyte ratio serves as a potential biomarker for atezolizumab-treated patients with extensive stage small cell lung cancer.Semantic proximity Read ↗

Blood-based tumor mutational burden as a biomarker for atezolizumab in non-small cell lung cancer: the phase 2 B-F1RST trial.Semantic proximity Read ↗

Evaluation of Blood Tumor Mutation Burden for the Efficacy of Second-Line Atezolizumab Treatment in Non-Small Cell Lung Cancer: BUDDY Trial.Semantic proximity Read ↗

Blood-based tumor mutational burden as a predictor of clinical benefit in non-small-cell lung cancer patients treated with atezolizumab.Semantic proximity Read ↗

ctDNA-adjusted bTMB as a predictive biomarker for patients with NSCLC treated with PD-(L)1 inhibitors.Semantic proximity Read ↗

Pan-cancer population pharmacokinetics and exposure-safety and -efficacy analyses of atezolizumab in patients with high tumor mutational burden.Semantic proximity Read ↗

Atezolizumab prolongs overall survival over docetaxel in advanced non-small-cell lung cancer patients harboring STK11 or KEAP1 mutation.Semantic proximity Read ↗

On-treatment blood TMB as predictors for camrelizumab plus chemotherapy in advanced lung squamous cell carcinoma: biomarker analysis of a phase III trial.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.